Companies › CyanVac
2 active drug programs in 2 registered trials: 2 Phase 1; Infectious disease; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| CVM150 Live PIV5-based mumps virus vaccine expressing mumps F and HN proteins | – | Phase 1 | Mumps | Dec 2027 |
| CVM26 Live attenuated mumps virus vaccine with V and SH protein expression removed | – | Phase 1 | Mumps | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06967181 | CVM150 | Phase 1 | Mumps | Infectious disease | Dec 2027 |
| NCT06967181 | CVM26 | Phase 1 | Mumps | Infectious disease | Dec 2027 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.